Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alnylam Pharmaceuticals, Inc. (ALNY) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (8)	2/9/2005 11:35:39 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 166

And alny is up on this news? Medtronic and Alnylam Pharmaceuticals to Collaborate on Potential Treatments for Major Neurodegenerative Diseases Wednesday February 9, 8:01 am ET Alliance will focus on drug-device combinations incorporating RNAi therapeutics MINNEAPOLIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 9, 2005-- Medtronic, Inc. (NYSE:MDT - News), the world's leading medical technology company, and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - News), a leading RNAi therapeutics company, today announced that they will collaborate to pursue potential therapies designed to treat neurodegenerative disorders such as Huntington's, Alzheimer's and Parkinson's disease. The collaboration will focus on developing novel drug-device combinations incorporating RNAi therapeutics. RNAi, or RNA interference, refers to a technique for silencing targeted genes in a cell, inhibiting their ability to produce particular proteins involved in specific diseases. Initial development will focus on delivering RNAi therapeutics to specific areas of the brain using novel infusion systems. Under terms of the collaboration agreement, after successful completion of an initial joint technology development program and a joint decision to initiate product development, Alnylam would be responsible for the discovery and early development of candidate RNAi therapeutics, and Medtronic would be responsible for late-stage development and commercialization of any drug-device products that result. Medtronic also would adapt or develop medical devices to deliver the candidate RNAi therapeutics to targeted locations in the nervous system.